Isoxazolopyrimidine-Based Inhibitors of

Area of Science:

• Medicinal Chemistry
• Parasitology
• Drug Discovery

Background:

• Malaria remains a significant global health burden, causing nearly 0.5 million deaths annually and affecting over 90 endemic countries.
• Increasing drug resistance threatens current malaria treatment programs, necessitating the development of novel therapeutic strategies.
• Dihydroorotate dehydrogenase (DHODH) is a validated antimalarial drug target, with inhibitors like triazolopyrimidines (e.g., DSM265) in clinical development.

Purpose of the Study:

• To investigate a newly discovered series of isoxazolopyrimidine compounds as potential antimalarial agents.
• To determine if these isoxazolopyrimidines target DHODH and could be developed into viable drug candidates.
• To evaluate the antimalarial efficacy and pharmacokinetic properties of the identified isoxazolopyrimidine analogues.

Main Methods:

• Phenotypic screening to identify initial hit compounds.
• Hit-to-lead medicinal chemistry optimization to improve potency and drug-like properties.
• In vivo testing in preclinical models to assess antimalarial activity.
• Pharmacokinetic studies to evaluate drug metabolism and disposition.

Main Results:

• A novel series of isoxazolopyrimidines was discovered, targeting DHODH.
• Medicinal chemistry efforts yielded potent analogues with demonstrated in vivo antimalarial activity.
• Isoxazolopyrimidines exhibited more rapid metabolism compared to triazolopyrimidine analogues.
• Pharmacokinetic profiles indicated limitations for achieving a single-dose treatment regimen.

Conclusions:

• Isoxazolopyrimidines represent a promising new chemical class for targeting DHODH in malaria.
• Further optimization is required to address the rapid metabolism and improve pharmacokinetic properties for potential clinical development.
• The findings contribute to the ongoing search for effective and resistance-breaking antimalarial therapies.